Literature DB >> 17973650

Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII).

G J Miller1, H A Ireland, J A Cooper, K A Bauer, J H Morrissey, S E Humphries, M P Esnouf.   

Abstract

OBJECTIVE: To determine whether activation of coagulation increases in parallel with inflammation and whether coagulation activation markers (CAMs) are independently associated with coronary heart disease (CHD), in the prospective study, NPHSII.
METHODS: Surveillance of 2997 men between 50 and 63 years yielded 314 first CHD events during 36507 person-years of observation. The plasma levels of activated factor XII (FXIIa), the peptides released upon activation of factor X (FXpep) and factor IX (FIXpep), activated factor VII (FVIIa), prothrombin fragment 1 + 2 (F1 + 2) and fibrinopeptide A (FpA) served as indices of activity along the coagulation pathway. C reactive protein (CRP) provided a marker of inflammatory activity.
RESULTS: While borderline or significant correlations were identified for each CAM with inflammation, as determined by CRP levels, these did not reach as high a numerical value as was shown for fibrinogen with CRP. FVIIa and FIXpep possessed independent associations with CHD: a one SD increase in adjusted FIXpep and FVIIa level was associated with a relative hazard of 1.20 (95% CI 1.00-1.43) and 0.70 (CI 0.58-0.86), respectively, using a group including all CHD events, compared with 'no-event'.
CONCLUSIONS: Inflammation has significant but minimal impact upon CAMs of the extrinsic coagulation pathway. Reduced FVIIa and increased FIXpep levels were found to be significant, independent, predictors of CHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17973650     DOI: 10.1111/j.1538-7836.2007.02819.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

1.  Factor IX and deep vein thrombosis.

Authors:  Gordon Lowe
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

2.  Factor VII and incidence of myocardial infarction in a Japanese population: The Jichi Medical School Cohort Study.

Authors:  Takuya Shiraishi; Shizukiyo Ishikawa; Kazuomi Kario; Kazunori Kayaba; Eiji Kajii
Journal:  J Clin Lab Anal       Date:  2017-02-13       Impact factor: 2.352

Review 3.  Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?

Authors:  Becky Woodruff; Bruce Sullenger; Richard C Becker
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

4.  Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease.

Authors:  Kazumasa Yamagishi; Nena Aleksic; Peter J Hannan; Aaron R Folsom
Journal:  J Atheroscler Thromb       Date:  2010-04-07       Impact factor: 4.928

5.  Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men.

Authors:  G Ken-Dror; F Drenos; S E Humphries; P J Talmud; A D Hingorani; M Kivimäki; M Kumari; K A Bauer; J H Morrissey; H A Ireland
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

6.  Changes in haemostatic and platelet activation markers in non-dipper hypertensive patients.

Authors:  Athanasia Agorasti; Efthimia Mourvati; Theodoros Trivellas; Vasilios Papadopoulos; Ioanna Bazntiara; Anna Christoforidou; Ploumis Passadakis
Journal:  Int Urol Nephrol       Date:  2011-03-09       Impact factor: 2.370

7.  FVII, FVIIa, and downstream markers of extrinsic pathway activation differ by EPCR Ser219Gly variant in healthy men.

Authors:  Helen A Ireland; Jackie A Cooper; Fotios Drenos; Jayshree Acharya; Jacqueline P Mitchell; Ken A Bauer; James H Morrissey; M Peter Esnouf; Stephen E Humphries
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-20       Impact factor: 8.311

8.  A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.

Authors:  Thomas J Povsic; John P Vavalle; Laura H Aberle; Jaroslaw D Kasprzak; Mauricio G Cohen; Roxana Mehran; Christoph Bode; Christopher E Buller; Gilles Montalescot; Jan H Cornel; Andrzej Rynkiewicz; Michael E Ring; Uwe Zeymer; Madhu Natarajan; Nicolas Delarche; Steven L Zelenkofske; Richard C Becker; John H Alexander
Journal:  Eur Heart J       Date:  2012-08-02       Impact factor: 29.983

9.  Free protein S level as a risk factor for coronary heart disease and stroke in a prospective cohort study of healthy United Kingdom men.

Authors:  Gie Ken-Dror; Jackie A Cooper; Steve E Humphries; Fotios Drenos; Helen A Ireland
Journal:  Am J Epidemiol       Date:  2011-09-12       Impact factor: 4.897

10.  Prothrombotic markers in patients with acute myocardial infarction and left ventricular thrombus formation treated with pci and dual antiplatelet therapy.

Authors:  Svein Solheim; Ingebjørg Seljeflot; Ketil Lunde; Vibeke Bratseth; Svend Aakhus; Kolbjørn Forfang; Harald Arnesen
Journal:  Thromb J       Date:  2013-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.